Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

被引：0
|
作者：
Pere Gascón
Matti Aapro
Heinz Ludwig
Carsten Bokemeyer
Mario Boccadoro
Matthew Turner
Kris Denhaerynck
Karen MacDonald
Ivo Abraham
机构：
[1] University of Barcelona,Division of Medical Oncology, Department of Hematology
[2] Clinique de Genolier,Oncology, Hospital Clínic de Barcelona
[3] Wilhelminenspital,Institut Multidisciplinaire d’Oncologie
[4] Universitaetsklinikum Hamburg Eppendorf,Medizinische Abteilung I–Onkologie und Haematologie
[5] Universitaria S. Giovanni Battista di Torino,Dipartimento di Oncologia e Ematologia, Azienda Ospedaliero
[6] Sandoz Biopharmaceuticals,Center for Health Outcomes and PharmacoEconomic Research
[7] University of Arizona,undefined
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：927 / 927
相关论文
共 50 条
  • [41] Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia
    McBride, Ali
    Campbell, Kim
    Bikkina, Mohan
    MacDonald, Karen
    Abraham, Ivo
    Balu, Sanjeev
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (06) : 606 - 609
  • [42] Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
    Advani, S. H.
    Achreckar, Suvarna
    Thomas, Dennis
    Krishnankutty, Binny
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2010, 31 (03) : 79 - 82
  • [43] Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia
    Didier Kamioner
    Stefan Fruehauf
    Fréderic Maloisel
    Laurent Cals
    Stéphane Lepretre
    Christian Berthou
    BMC Cancer, 13
  • [44] Biosimilar filgrastim in the treatment and prevention of chemotherapy-induced neutropenia in patients with breast cancer: A sub-analysis of the NEXT study
    Kamioner, D.
    Lepretre, S.
    Maloisel, F.
    Berthou, C.
    Albrand, H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S242 - S243
  • [45] Biosimilar filgrastim in the treatment and prevention of chemotherapy-induced neutropenia in patients with solid tumours: a sub-analysis of the NEXT study
    Maloisel, F.
    Lepretre, S.
    Kamioner, D.
    Berthou, C.
    Albrand, H.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S307 - S308
  • [46] Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia
    Kamioner, Didier
    Fruehauf, Stefan
    Maloisel, Frederic
    Cals, Laurent
    Lepretre, Stephane
    Berthou, Christian
    BMC CANCER, 2013, 13
  • [47] Prophylaxis of chemotherapy-induced neutropenia (CIN) with filgrastim biosimilar Ratiograstim® - results from the prospective non-interventional study (NIS) "RatioNeu"
    Jungberg, P.
    Juenemann, R.
    Schroeder, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 38 - 38
  • [48] Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia
    Ratti, Margherita
    Tomasello, Gianluca
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2015, 8 (01) : 15 - 24
  • [49] EXPANDED ACCESS TO PEMBROLIZUMAB FROM COST-SAVINGS GENERATED BY BIOSIMILAR FILGRASTIM (BIOSIM-FIL) IN THE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED (FEBRILE) NEUTROPENIA (CIN/FN): SIMULATION STUDY
    McBride, A.
    Balu, S.
    Campbell, K.
    Bikkina, M.
    MacDonald, K.
    Abraham, I
    VALUE IN HEALTH, 2017, 20 (09) : A443 - A443
  • [50] Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia
    Bal, Abhijit M.
    Gould, Ian M.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (05) : 501 - 509
12345